Ceregene therapy for Parkinson's fails Phase 2 trial San Diego Union Tribune, CA - Nov 27, 2008 The company had been developing the Parkinson's therapy with the help of more than $2 million from the nonprofit Michael J. Fox Foundation. ...
Neurologix Announces Third Quarter 2008 Financial Results Centre Daily Times, PA - Nov 14, 2008 "Patient screening for our Phase 2 clinical trial of our investigational gene therapy procedure for the treatment of Parkinson's disease is well underway at ...OTC:NRGX
UK stem cell work under threat BBC News, UK - Nov 24, 2008 "The Department of Health and its Gene Therapy Advisory Committee are currently working with other regulators in the field to produce a 'Regulatory Route ...
Oxford BioMedica Announces Two Scientific Presentations of ... PharmaLive.com (press release), PA - Nov 14, 2008 Presentation at 9.40am CET on Friday, 14 November (session: Progress in Clinical Gene Therapy; presentation title: ProSavin: A gene therapy for Parkinson?s ...LON:OXB
Vitamin D, A Gene-Regulating Super Nutrient Natural News.com, AZ - Nov 6, 2008 An interesting study compared vitamin D levels in older Americans to Parkinson's and Alzheimer's disease. Patients with Parkinson's were 55% more likely to ...
Brain stimulation may help obsessive disorder Reuters UK, UK - Nov 12, 2008 By Gene Emery BOSTON (Reuters) - Stimulating an area near the base of the brain may help people with otherwise untreatable obsessive-compulsive disorder, ...
Parkinson's treatment symposium later this month Greenville News, SC - The three will discuss drugs used in the treatment of Parkinson's disease, the role of physical therapy, and coping strategies for caregivers, ...
Pennies put Parkinson's research on roll Arizona Republic, AZ - Aug 4, 2008 ... a cure for the degenerative disease. The campaign is the pet project of Bruce Florence, a Fountain Hills resident and the founder of a local Parkinson's...
Join the fight against Parkinson?s nowwearetalking, Australia - ... diagnosed with Parkinson?s at 28, Nerissa set up POP (Perspectives on Parkinson?s) ? a foundation dedicated to raising funds for research into a cure...
Shun Drugs With Two Letters After The Name And Save The Consumerist, NY - There are a few exceptions where an extended formula works better, like short-acting calcium channel blockers like nifedipine, or Parkinson's treatment drug ...
Ropinirole for the treatment of early Parkinson's disease - CH Adler, KD Sethi, RA Hauser, TL Davis, JP … - Neurology, 1997 - AAN Enterprises ... Ropinirole for the treatment of early Parkinson's disease. ... Med. J. Home page A M?nchau
and KP Bhatia Pharmacological treatment of Parkinson's disease Postgrad. ...
Subcutaneous apomorphine in the treatment of Parkinson's disease - JP Frankel, AJ Lees, PA Kempster, GM Stern - British Medical Journal, 1990 - jnnp.bmj.com ... Journal of Neurology, Neurosurgery, and Psychiatry, 1990, Vol 53, 96-101. PAPERS.
Subcutaneous apomorphine in the treatment of Parkinson's disease. ...
Doctors are to attempt to cure patients suffering from Parkinson's disease with pioneering gene therapy.
The treatment involves injections of a virus that has been genetically modified to carry genes which create vital brain chemicals.
The technique has proved so successful on animals that researchers are about to try it on 12 Parkinson's patients.
They hope it will calm the tremors and other movement disorders of the devastating brain disorder.
An effective new therapy for Parkinson's would be a major breakthrough.
The disease affects more than 120,000 people in Britain and experts warn numbers are rising as the population gets older. Although most of the 10,000 people diagnosed each year are aged over 60, one in 20 is under 40. Actor Michael J. Fox and boxer Muhammad Ali are sufferers.
Currently, Parkinson's is incurable. Treatment with the drug levodopa can restore normal movement in patients with early signs of the disease, but it gradually loses effectiveness.
Dr Matthew During and Dr Michael Kaplitt, who have pioneered the gene therapy treatment, say they had just been given approval to use it in a trial on a dozen patients.
The approval was based, in part, on the encouraging results of laboratory studies published in a recent issue of the journal Science.
Dr Kaplitt, a Parkinson's researcher at the Weill Medical College of Cornell University in New York, said the trial will start late this year and involve patients who have exhausted all standard treatments.
Gene therapy involves silencing faulty genes responsible for defects, or switching on genes that could suppress illnesses.
One way of doing this is to use a virus, such as the one that causes the common cold, which has been engineered so that it is harmless. It can then be used to carry new genes into the body.
'We are encouraged that in addition to quieting symptoms, we have evidence that suggests it may arrest or delay disease progression,' says Dr During.
